In a single center retrospective study conducted in Korea, the median progression-free survival for ICI among 13 patients with RET fusion-positive NSCLC treated with ICI was 2.1 (95% CI: 1.6–2.6) months, and the ORR was 7.7% (64). Here, RET is linked to non-small cell lung carcinoma.